Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Argus Health
Queensland Health
Fuji
Federal Trade Commission
Boehringer Ingelheim
Cipla
AstraZeneca
US Army
Citi

Generated: June 21, 2018

DrugPatentWatch Database Preview

Details for Patent: 7,615,545

« Back to Dashboard

Summary for Patent: 7,615,545
Title:Oral contraceptives to prevent pregnancy and diminish premenstrual symptomatology
Abstract:This invention relates to a method of preventing pregnancy and treating PMS including PMDD. More particularly, the invention relates to a method, which involves administering one of several combination oral contraceptive regimens in combination with an antidepressant and a kit containing the same.
Inventor(s): Bell; Robert G. (Palm Harbor, FL), Ben-Maimon; Carole (Merion, PA), Iskold; Beata (Livingston, NJ)
Assignee: Duramed Pharmaceuticals, Inc. (Pomona, NY)
Application Number:11/892,014
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 7,615,545
Patent Claim Types:
see list of patent claims
Use; Delivery; Composition;

Drugs Protected by US Patent 7,615,545

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Teva Branded Pharm LOSEASONIQUE ethinyl estradiol; levonorgestrel TABLET;ORAL 022262-001 Oct 24, 2008 AB RX No No ➤ Sign Up ➤ Sign Up PREVENTION OF PREGNANCY ➤ Sign Up
Teva Branded Pharm SEASONIQUE ethinyl estradiol; levonorgestrel TABLET;ORAL 021840-001 May 25, 2006 AB RX Yes Yes ➤ Sign Up ➤ Sign Up PREVENTION OF PREGNANCY ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 7,615,545

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,680,084 Oral contraceptives to prevent pregnancy and diminish premenstrual symptomatology ➤ Sign Up
7,320,969 Oral contraceptives to prevent pregnancy and diminish premenstrual symptomatology ➤ Sign Up
8,338,396 Oral contraceptives to prevent pregnancy and diminish premenstrual symptomatology ➤ Sign Up
7,858,605 Oral contraceptives to prevent pregnancy and diminish premenstrual symptomatology ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

AstraZeneca
Argus Health
Harvard Business School
Teva
Accenture
Mallinckrodt
US Department of Justice
Healthtrust
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.